| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Adenoviridae | 50 | 2016 | 1492 | 2.710 |
Why?
|
| Genetic Therapy | 36 | 2010 | 1714 | 2.410 |
Why?
|
| Lung Neoplasms | 43 | 2023 | 12020 | 1.910 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 26 | 2022 | 5565 | 1.870 |
Why?
|
| Genetic Vectors | 37 | 2016 | 1857 | 1.740 |
Why?
|
| Auranofin | 6 | 2019 | 36 | 1.720 |
Why?
|
| Telomerase | 11 | 2010 | 547 | 1.650 |
Why?
|
| Membrane Glycoproteins | 12 | 2006 | 1095 | 1.570 |
Why?
|
| Tumor Necrosis Factor-alpha | 12 | 2006 | 1586 | 1.500 |
Why?
|
| Apoptosis | 44 | 2019 | 7753 | 1.310 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 20 | 2005 | 1542 | 1.310 |
Why?
|
| Indoles | 4 | 2015 | 1028 | 1.170 |
Why?
|
| Oncolytic Virotherapy | 6 | 2009 | 234 | 1.070 |
Why?
|
| TNF-Related Apoptosis-Inducing Ligand | 16 | 2010 | 210 | 1.020 |
Why?
|
| Proto-Oncogene Proteins | 18 | 2019 | 2618 | 1.000 |
Why?
|
| Cell Line, Tumor | 42 | 2024 | 14830 | 0.950 |
Why?
|
| Antineoplastic Agents | 18 | 2021 | 14622 | 0.900 |
Why?
|
| Promoter Regions, Genetic | 16 | 2013 | 3213 | 0.890 |
Why?
|
| Insulin-Like Growth Factor Binding Protein 2 | 2 | 2013 | 86 | 0.870 |
Why?
|
| Xenograft Model Antitumor Assays | 25 | 2024 | 3909 | 0.850 |
Why?
|
| Drug Resistance, Neoplasm | 18 | 2023 | 5407 | 0.840 |
Why?
|
| Mutation | 20 | 2023 | 15904 | 0.800 |
Why?
|
| eIF-2 Kinase | 5 | 2019 | 166 | 0.770 |
Why?
|
| ras Proteins | 3 | 2015 | 804 | 0.770 |
Why?
|
| Tumor Cells, Cultured | 35 | 2018 | 5758 | 0.730 |
Why?
|
| Clinical Laboratory Services | 1 | 2020 | 39 | 0.700 |
Why?
|
| Pyrimidines | 4 | 2018 | 3662 | 0.700 |
Why?
|
| Pyrazoles | 4 | 2020 | 1539 | 0.690 |
Why?
|
| Neoplasms, Experimental | 6 | 2008 | 785 | 0.690 |
Why?
|
| Mice | 61 | 2024 | 35572 | 0.680 |
Why?
|
| Animals | 76 | 2024 | 61992 | 0.650 |
Why?
|
| ErbB Receptors | 10 | 2023 | 2376 | 0.650 |
Why?
|
| Glutathione | 4 | 2021 | 375 | 0.650 |
Why?
|
| Thioredoxin-Disulfide Reductase | 1 | 2018 | 9 | 0.650 |
Why?
|
| Glutathione Reductase | 1 | 2018 | 21 | 0.650 |
Why?
|
| Glutamate-Cysteine Ligase | 1 | 2018 | 29 | 0.640 |
Why?
|
| Synthetic Lethal Mutations | 1 | 2018 | 32 | 0.630 |
Why?
|
| Transgenes | 8 | 2002 | 576 | 0.630 |
Why?
|
| Thioredoxins | 1 | 2018 | 50 | 0.630 |
Why?
|
| Apoptosis Regulatory Proteins | 12 | 2006 | 623 | 0.610 |
Why?
|
| Mice, Nude | 26 | 2022 | 4329 | 0.610 |
Why?
|
| Genes, p53 | 8 | 2007 | 1140 | 0.600 |
Why?
|
| Genetic Engineering | 4 | 2018 | 295 | 0.590 |
Why?
|
| Oncolytic Viruses | 3 | 2009 | 164 | 0.570 |
Why?
|
| STAT3 Transcription Factor | 3 | 2012 | 1135 | 0.550 |
Why?
|
| Colonic Neoplasms | 7 | 2010 | 1430 | 0.540 |
Why?
|
| bcl-2-Associated X Protein | 18 | 2005 | 374 | 0.530 |
Why?
|
| Thiazoles | 2 | 2013 | 723 | 0.520 |
Why?
|
| Cell Survival | 15 | 2019 | 3061 | 0.520 |
Why?
|
| Humans | 136 | 2024 | 270370 | 0.500 |
Why?
|
| Arylsulfotransferase | 1 | 2015 | 20 | 0.490 |
Why?
|
| Betacoronavirus | 1 | 2020 | 513 | 0.490 |
Why?
|
| Gene Expression Regulation, Neoplastic | 18 | 2020 | 9040 | 0.490 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2017 | 714 | 0.480 |
Why?
|
| Transfection | 16 | 2020 | 3118 | 0.470 |
Why?
|
| Circulating Tumor DNA | 1 | 2017 | 274 | 0.470 |
Why?
|
| Phosphatidylinositol 3-Kinases | 4 | 2023 | 1710 | 0.460 |
Why?
|
| Mice, Inbred BALB C | 15 | 2022 | 2455 | 0.460 |
Why?
|
| RNA Polymerase II | 2 | 2011 | 184 | 0.450 |
Why?
|
| Pharmacogenetics | 1 | 2015 | 267 | 0.450 |
Why?
|
| Disease Models, Animal | 8 | 2022 | 7370 | 0.440 |
Why?
|
| Proto-Oncogene Proteins c-akt | 5 | 2023 | 2075 | 0.440 |
Why?
|
| Neoplasms | 14 | 2024 | 15897 | 0.430 |
Why?
|
| Prodrugs | 1 | 2014 | 226 | 0.420 |
Why?
|
| Focal Adhesion Protein-Tyrosine Kinases | 1 | 2013 | 163 | 0.420 |
Why?
|
| Drug Discovery | 2 | 2017 | 329 | 0.420 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 624 | 0.410 |
Why?
|
| Virus Replication | 4 | 2008 | 778 | 0.410 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 698 | 0.410 |
Why?
|
| DNA, Neoplasm | 2 | 2017 | 1957 | 0.400 |
Why?
|
| Phenylketonurias | 6 | 1998 | 24 | 0.400 |
Why?
|
| Blotting, Western | 13 | 2017 | 3592 | 0.390 |
Why?
|
| Precision Medicine | 3 | 2017 | 1207 | 0.380 |
Why?
|
| Saccharomyces cerevisiae Proteins | 3 | 2001 | 470 | 0.380 |
Why?
|
| TOR Serine-Threonine Kinases | 3 | 2023 | 1565 | 0.380 |
Why?
|
| Cell Proliferation | 13 | 2021 | 7241 | 0.370 |
Why?
|
| Gene Transfer Techniques | 11 | 2004 | 804 | 0.370 |
Why?
|
| DNA-Binding Proteins | 13 | 2021 | 5001 | 0.370 |
Why?
|
| Mice, SCID | 4 | 2019 | 1830 | 0.370 |
Why?
|
| JNK Mitogen-Activated Protein Kinases | 1 | 2011 | 303 | 0.360 |
Why?
|
| Cystine | 2 | 2021 | 33 | 0.360 |
Why?
|
| Thiazolidines | 2 | 2006 | 15 | 0.350 |
Why?
|
| Vimentin | 2 | 2022 | 255 | 0.340 |
Why?
|
| Mitogen-Activated Protein Kinase 8 | 2 | 2008 | 44 | 0.340 |
Why?
|
| Adenocarcinoma | 6 | 2019 | 7883 | 0.330 |
Why?
|
| Protein Kinase Inhibitors | 7 | 2023 | 4960 | 0.330 |
Why?
|
| Enzyme Activation | 6 | 2013 | 1814 | 0.320 |
Why?
|
| AMP-Activated Protein Kinases | 3 | 2024 | 404 | 0.310 |
Why?
|
| Gene Targeting | 3 | 2001 | 314 | 0.310 |
Why?
|
| Phenylalanine Hydroxylase | 6 | 1998 | 23 | 0.310 |
Why?
|
| Mitogen-Activated Protein Kinase 9 | 1 | 2008 | 32 | 0.310 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2017 | 2354 | 0.310 |
Why?
|
| Gene Expression | 14 | 2013 | 3638 | 0.310 |
Why?
|
| Vaccinia virus | 1 | 2008 | 85 | 0.310 |
Why?
|
| Biomarkers, Tumor | 7 | 2019 | 10694 | 0.300 |
Why?
|
| Flow Cytometry | 14 | 2019 | 3045 | 0.300 |
Why?
|
| Dose-Response Relationship, Drug | 5 | 2018 | 5071 | 0.300 |
Why?
|
| DNA Damage | 3 | 2019 | 1982 | 0.300 |
Why?
|
| Heterocyclic Compounds, 3-Ring | 3 | 2013 | 153 | 0.290 |
Why?
|
| Drug Screening Assays, Antitumor | 4 | 2015 | 563 | 0.290 |
Why?
|
| Capsid Proteins | 2 | 1999 | 219 | 0.290 |
Why?
|
| Heterografts | 3 | 2022 | 741 | 0.280 |
Why?
|
| Structure-Activity Relationship | 4 | 2021 | 978 | 0.280 |
Why?
|
| Mice, Inbred NOD | 2 | 2019 | 900 | 0.270 |
Why?
|
| Caspases | 7 | 2019 | 679 | 0.270 |
Why?
|
| Genes, ras | 2 | 2006 | 679 | 0.270 |
Why?
|
| Heat-Shock Proteins | 1 | 2008 | 330 | 0.270 |
Why?
|
| Aniline Compounds | 2 | 2020 | 206 | 0.270 |
Why?
|
| Signal Transduction | 9 | 2024 | 12100 | 0.270 |
Why?
|
| Membrane Proteins | 9 | 2005 | 2928 | 0.260 |
Why?
|
| Mitochondria | 10 | 2024 | 1300 | 0.260 |
Why?
|
| Gene Deletion | 5 | 2021 | 1471 | 0.250 |
Why?
|
| Antirheumatic Agents | 3 | 2018 | 229 | 0.250 |
Why?
|
| Immunotherapy | 2 | 2018 | 3550 | 0.250 |
Why?
|
| Proto-Oncogene Proteins c-met | 2 | 2019 | 427 | 0.250 |
Why?
|
| Adenine | 3 | 2018 | 668 | 0.250 |
Why?
|
| Thioredoxin Reductase 1 | 2 | 2016 | 15 | 0.250 |
Why?
|
| Mitogen-Activated Protein Kinases | 2 | 2005 | 668 | 0.240 |
Why?
|
| Histone Deacetylases | 2 | 2017 | 364 | 0.240 |
Why?
|
| Ethanolamines | 1 | 2004 | 37 | 0.240 |
Why?
|
| Gene Expression Regulation | 5 | 2008 | 4135 | 0.230 |
Why?
|
| Bystander Effect | 1 | 2004 | 22 | 0.230 |
Why?
|
| Adenovirus E1A Proteins | 5 | 2010 | 165 | 0.230 |
Why?
|
| Chlorobenzenes | 1 | 2004 | 33 | 0.230 |
Why?
|
| Erlotinib Hydrochloride | 2 | 2016 | 398 | 0.230 |
Why?
|
| Green Fluorescent Proteins | 7 | 2010 | 692 | 0.230 |
Why?
|
| Benzimidazoles | 2 | 2022 | 437 | 0.230 |
Why?
|
| Enzyme Inhibitors | 2 | 2011 | 1946 | 0.230 |
Why?
|
| Electron Transport Complex I | 1 | 2024 | 67 | 0.230 |
Why?
|
| Drug Synergism | 4 | 2022 | 1359 | 0.230 |
Why?
|
| Cancer Vaccines | 2 | 2007 | 754 | 0.230 |
Why?
|
| S Phase | 1 | 2004 | 288 | 0.220 |
Why?
|
| Amino Acid Transport System y+ | 2 | 2021 | 32 | 0.220 |
Why?
|
| Adenoviruses, Human | 2 | 2004 | 191 | 0.220 |
Why?
|
| RNA, Small Interfering | 8 | 2013 | 2197 | 0.220 |
Why?
|
| Cell Line | 10 | 2022 | 5339 | 0.220 |
Why?
|
| Carcinoma, Hepatocellular | 3 | 2005 | 2161 | 0.220 |
Why?
|
| Insulin-Like Growth Factor Binding Proteins | 1 | 2013 | 63 | 0.220 |
Why?
|
| Transcription Factors | 5 | 2018 | 5438 | 0.210 |
Why?
|
| Cytomegalovirus | 1 | 2006 | 493 | 0.210 |
Why?
|
| RNA, Neoplasm | 3 | 2017 | 806 | 0.210 |
Why?
|
| Piperidines | 3 | 2018 | 1086 | 0.210 |
Why?
|
| Cyclins | 1 | 2004 | 467 | 0.210 |
Why?
|
| Hepatolenticular Degeneration | 2 | 1992 | 44 | 0.210 |
Why?
|
| Peptoids | 1 | 2022 | 4 | 0.200 |
Why?
|
| TATA Box | 2 | 2001 | 42 | 0.200 |
Why?
|
| Luminescent Proteins | 3 | 2001 | 300 | 0.200 |
Why?
|
| Inhibitory Concentration 50 | 2 | 2013 | 285 | 0.200 |
Why?
|
| Viral Proteins | 2 | 2020 | 492 | 0.200 |
Why?
|
| Immunocompetence | 2 | 2006 | 73 | 0.200 |
Why?
|
| Female | 46 | 2024 | 148592 | 0.190 |
Why?
|
| Factor IX | 3 | 1996 | 26 | 0.190 |
Why?
|
| bcl-2 Homologous Antagonist-Killer Protein | 8 | 2005 | 75 | 0.190 |
Why?
|
| Kv Channel-Interacting Proteins | 1 | 2021 | 31 | 0.190 |
Why?
|
| Fungal Proteins | 2 | 2002 | 271 | 0.180 |
Why?
|
| Colorectal Neoplasms | 4 | 2022 | 3700 | 0.180 |
Why?
|
| Anaphase | 1 | 2020 | 54 | 0.180 |
Why?
|
| Carcinoembryonic Antigen | 1 | 2001 | 231 | 0.180 |
Why?
|
| Liver Neoplasms | 4 | 2005 | 4803 | 0.180 |
Why?
|
| Cell Nucleus | 3 | 2018 | 1717 | 0.180 |
Why?
|
| Adenovirus E2 Proteins | 2 | 1999 | 3 | 0.180 |
Why?
|
| Adenovirus E1 Proteins | 2 | 1999 | 6 | 0.180 |
Why?
|
| Tumor Suppressor Proteins | 3 | 2016 | 1900 | 0.170 |
Why?
|
| Pentose Phosphate Pathway | 1 | 2020 | 71 | 0.170 |
Why?
|
| Cysteine | 1 | 2021 | 213 | 0.170 |
Why?
|
| Neoplasm Staging | 6 | 2019 | 13998 | 0.170 |
Why?
|
| Gene Expression Regulation, Viral | 2 | 1997 | 197 | 0.170 |
Why?
|
| Recombinant Fusion Proteins | 3 | 2001 | 1640 | 0.170 |
Why?
|
| Mechanistic Target of Rapamycin Complex 1 | 1 | 2021 | 275 | 0.170 |
Why?
|
| Muscle, Skeletal | 2 | 2017 | 1289 | 0.170 |
Why?
|
| Epithelial Cells | 4 | 2022 | 1872 | 0.170 |
Why?
|
| Mice, Inbred C3H | 4 | 2007 | 402 | 0.170 |
Why?
|
| Adenovirus Early Proteins | 1 | 1999 | 12 | 0.170 |
Why?
|
| Cyclin-Dependent Kinase 2 | 1 | 2020 | 252 | 0.160 |
Why?
|
| Clinical Trials as Topic | 3 | 2018 | 3844 | 0.160 |
Why?
|
| Polymorphism, Restriction Fragment Length | 5 | 1996 | 275 | 0.160 |
Why?
|
| Deoxycytidine | 1 | 2005 | 1390 | 0.160 |
Why?
|
| Unfolded Protein Response | 1 | 2019 | 112 | 0.160 |
Why?
|
| Quinazolines | 2 | 2014 | 956 | 0.160 |
Why?
|
| Protein Kinase C-delta | 1 | 2018 | 42 | 0.160 |
Why?
|
| Phosphotransferases (Alcohol Group Acceptor) | 1 | 2019 | 143 | 0.160 |
Why?
|
| Antigens, CD20 | 1 | 2019 | 207 | 0.160 |
Why?
|
| Hemophilia B | 2 | 1995 | 14 | 0.160 |
Why?
|
| Viral Structural Proteins | 1 | 1998 | 61 | 0.160 |
Why?
|
| Protein-Tyrosine Kinases | 2 | 2017 | 1839 | 0.160 |
Why?
|
| Cell Cycle Proteins | 3 | 2019 | 2117 | 0.150 |
Why?
|
| Proto-Oncogene Proteins c-mdm2 | 1 | 2022 | 526 | 0.150 |
Why?
|
| Molecular Structure | 2 | 2022 | 529 | 0.150 |
Why?
|
| Quinolines | 2 | 2020 | 400 | 0.150 |
Why?
|
| Pancreatic Neoplasms | 4 | 2005 | 5250 | 0.150 |
Why?
|
| MAP Kinase Signaling System | 2 | 2022 | 884 | 0.150 |
Why?
|
| Tumor Suppressor Protein p53 | 6 | 2019 | 3654 | 0.150 |
Why?
|
| Carcinogenesis | 2 | 2021 | 1035 | 0.150 |
Why?
|
| Transplantation, Heterologous | 5 | 2006 | 1054 | 0.150 |
Why?
|
| Polymerase Chain Reaction | 9 | 2013 | 3471 | 0.150 |
Why?
|
| Proteolysis | 1 | 2019 | 377 | 0.150 |
Why?
|
| Phosphorylation | 4 | 2019 | 4947 | 0.150 |
Why?
|
| Combined Modality Therapy | 5 | 2008 | 9041 | 0.150 |
Why?
|
| Genes, Viral | 1 | 1997 | 257 | 0.140 |
Why?
|
| Kaplan-Meier Estimate | 2 | 2019 | 6256 | 0.140 |
Why?
|
| Muscle Fatigue | 1 | 2016 | 12 | 0.140 |
Why?
|
| Nuclear Receptor Co-Repressor 1 | 1 | 2017 | 66 | 0.140 |
Why?
|
| Mitogen-Activated Protein Kinase Kinases | 3 | 2022 | 383 | 0.140 |
Why?
|
| Lysosomes | 1 | 2019 | 345 | 0.140 |
Why?
|
| Immunity | 1 | 2019 | 355 | 0.140 |
Why?
|
| Mucopolysaccharidoses | 3 | 1986 | 7 | 0.140 |
Why?
|
| Reactive Oxygen Species | 4 | 2019 | 1006 | 0.140 |
Why?
|
| Physical Endurance | 1 | 2016 | 52 | 0.140 |
Why?
|
| Real-Time Polymerase Chain Reaction | 3 | 2016 | 1199 | 0.140 |
Why?
|
| Calcium | 1 | 2013 | 1587 | 0.140 |
Why?
|
| Simian virus 40 | 1 | 1997 | 242 | 0.140 |
Why?
|
| Lipid Metabolism | 2 | 2017 | 476 | 0.140 |
Why?
|
| Oxidative Phosphorylation | 1 | 2018 | 272 | 0.140 |
Why?
|
| Mice, Knockout | 4 | 2021 | 5716 | 0.140 |
Why?
|
| Genomics | 2 | 2017 | 2835 | 0.140 |
Why?
|
| Cell Cycle | 4 | 2018 | 2137 | 0.130 |
Why?
|
| Muscle Strength | 1 | 2016 | 104 | 0.130 |
Why?
|
| Hemophilia A | 1 | 1996 | 28 | 0.130 |
Why?
|
| Tissue Distribution | 2 | 2014 | 930 | 0.130 |
Why?
|
| DNA Helicases | 1 | 2018 | 450 | 0.130 |
Why?
|
| RNA | 1 | 2000 | 1064 | 0.130 |
Why?
|
| Physical Conditioning, Animal | 1 | 2016 | 115 | 0.130 |
Why?
|
| Neoplasm Transplantation | 6 | 2006 | 1556 | 0.130 |
Why?
|
| Anilides | 1 | 2017 | 294 | 0.120 |
Why?
|
| Genes, erbB-1 | 1 | 2015 | 104 | 0.120 |
Why?
|
| Oxygenases | 1 | 2014 | 26 | 0.120 |
Why?
|
| Amniotic Fluid | 2 | 1986 | 154 | 0.120 |
Why?
|
| Cell Movement | 3 | 2013 | 2472 | 0.120 |
Why?
|
| Neoplastic Stem Cells | 2 | 2013 | 1458 | 0.120 |
Why?
|
| Cell Division | 7 | 2021 | 2661 | 0.120 |
Why?
|
| Transduction, Genetic | 7 | 2002 | 494 | 0.120 |
Why?
|
| Amino Acid Sequence | 2 | 2020 | 4568 | 0.120 |
Why?
|
| Drug Stability | 1 | 2014 | 106 | 0.120 |
Why?
|
| Gene Frequency | 1 | 2017 | 1247 | 0.120 |
Why?
|
| Genes, Tumor Suppressor | 2 | 2014 | 1126 | 0.120 |
Why?
|
| Sulfur Radioisotopes | 4 | 1986 | 29 | 0.120 |
Why?
|
| PTEN Phosphohydrolase | 1 | 2019 | 1013 | 0.120 |
Why?
|
| Threonine | 1 | 2014 | 164 | 0.120 |
Why?
|
| Phenotype | 6 | 2020 | 6497 | 0.120 |
Why?
|
| Alleles | 4 | 2015 | 2591 | 0.120 |
Why?
|
| Genes | 2 | 1992 | 607 | 0.110 |
Why?
|
| Methionine | 1 | 2014 | 170 | 0.110 |
Why?
|
| DNA Primers | 5 | 2013 | 1497 | 0.110 |
Why?
|
| Benzodioxoles | 1 | 2013 | 29 | 0.110 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 2 | 2013 | 1280 | 0.110 |
Why?
|
| Lymphocytes | 1 | 2018 | 1272 | 0.110 |
Why?
|
| Homeostasis | 1 | 2018 | 926 | 0.110 |
Why?
|
| Checkpoint Kinase 1 | 1 | 2014 | 169 | 0.110 |
Why?
|
| Glucose | 2 | 2020 | 1222 | 0.110 |
Why?
|
| Evaluation Studies as Topic | 3 | 2006 | 453 | 0.110 |
Why?
|
| Receptors, Tumor Necrosis Factor | 2 | 2005 | 207 | 0.110 |
Why?
|
| Capsid | 3 | 1999 | 178 | 0.110 |
Why?
|
| Protein Array Analysis | 1 | 2016 | 502 | 0.110 |
Why?
|
| Arabidopsis Proteins | 2 | 2005 | 52 | 0.110 |
Why?
|
| Paclitaxel | 2 | 2013 | 2101 | 0.110 |
Why?
|
| B-Lymphocytes | 1 | 2019 | 1424 | 0.110 |
Why?
|
| Elafin | 1 | 2013 | 35 | 0.110 |
Why?
|
| Proteins | 4 | 2005 | 2042 | 0.110 |
Why?
|
| Repressor Proteins | 1 | 2021 | 1717 | 0.110 |
Why?
|
| Coxsackie and Adenovirus Receptor-Like Membrane Protein | 1 | 2012 | 40 | 0.110 |
Why?
|
| Mice, Inbred C57BL | 6 | 2009 | 7091 | 0.110 |
Why?
|
| Tumor Burden | 3 | 2013 | 2031 | 0.110 |
Why?
|
| Liver | 7 | 2005 | 3082 | 0.110 |
Why?
|
| Lymphoma, B-Cell | 1 | 2019 | 929 | 0.100 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 4 | 2013 | 3607 | 0.100 |
Why?
|
| Oligopeptides | 2 | 2005 | 447 | 0.100 |
Why?
|
| Base Sequence | 9 | 2004 | 5432 | 0.100 |
Why?
|
| Ovarian Neoplasms | 3 | 2003 | 4785 | 0.100 |
Why?
|
| Kidney Neoplasms | 3 | 2020 | 3107 | 0.100 |
Why?
|
| Fetal Diseases | 2 | 1995 | 455 | 0.100 |
Why?
|
| Skin | 3 | 1986 | 1270 | 0.100 |
Why?
|
| Oxidation-Reduction | 2 | 2012 | 705 | 0.100 |
Why?
|
| Prenatal Diagnosis | 2 | 1995 | 611 | 0.100 |
Why?
|
| Patient Outcome Assessment | 1 | 2013 | 246 | 0.100 |
Why?
|
| Microscopy, Fluorescence | 3 | 2013 | 766 | 0.100 |
Why?
|
| Receptor, EphA2 | 1 | 2013 | 139 | 0.100 |
Why?
|
| Programmed Cell Death 1 Receptor | 1 | 2018 | 1094 | 0.100 |
Why?
|
| Down-Regulation | 3 | 2004 | 2091 | 0.100 |
Why?
|
| Subcutaneous Tissue | 1 | 2011 | 57 | 0.100 |
Why?
|
| Cytochrome c Group | 2 | 2001 | 70 | 0.100 |
Why?
|
| Receptor, ErbB-2 | 2 | 2017 | 2650 | 0.100 |
Why?
|
| Cell Transformation, Neoplastic | 2 | 2015 | 2448 | 0.100 |
Why?
|
| B7-H1 Antigen | 1 | 2018 | 1080 | 0.100 |
Why?
|
| HeLa Cells | 2 | 2008 | 1685 | 0.100 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2019 | 1655 | 0.100 |
Why?
|
| Genetic Linkage | 2 | 1995 | 604 | 0.100 |
Why?
|
| Molecular Targeted Therapy | 2 | 2018 | 2391 | 0.100 |
Why?
|
| Spectrophotometry, Ultraviolet | 1 | 2011 | 74 | 0.100 |
Why?
|
| Molecular Sequence Data | 9 | 2003 | 6683 | 0.100 |
Why?
|
| Insulin Resistance | 1 | 2016 | 728 | 0.090 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 1 | 2015 | 678 | 0.090 |
Why?
|
| Insulin-Like Growth Factor Binding Protein 6 | 2 | 2000 | 7 | 0.090 |
Why?
|
| Thyroid Neoplasms | 1 | 2022 | 1876 | 0.090 |
Why?
|
| alpha Catenin | 1 | 2010 | 23 | 0.090 |
Why?
|
| Pandemics | 1 | 2020 | 1596 | 0.090 |
Why?
|
| Protons | 1 | 2013 | 482 | 0.090 |
Why?
|
| Nuclear Proteins | 2 | 2018 | 3440 | 0.090 |
Why?
|
| Drug Repositioning | 2 | 2021 | 53 | 0.090 |
Why?
|
| Prognosis | 5 | 2019 | 22473 | 0.090 |
Why?
|
| Male | 21 | 2019 | 128053 | 0.090 |
Why?
|
| Carcinoma, Squamous Cell | 3 | 2015 | 5585 | 0.090 |
Why?
|
| Genes, Reporter | 3 | 2009 | 820 | 0.090 |
Why?
|
| RNA Interference | 2 | 2018 | 1386 | 0.090 |
Why?
|
| Mitosis | 2 | 2005 | 680 | 0.090 |
Why?
|
| Photons | 1 | 2013 | 536 | 0.090 |
Why?
|
| Protein Kinases | 1 | 2014 | 902 | 0.090 |
Why?
|
| COS Cells | 3 | 2002 | 417 | 0.090 |
Why?
|
| Dasatinib | 1 | 2013 | 881 | 0.090 |
Why?
|
| Point Mutation | 1 | 1992 | 788 | 0.080 |
Why?
|
| Lung | 1 | 2021 | 3289 | 0.080 |
Why?
|
| Heterozygote | 1 | 1992 | 1056 | 0.080 |
Why?
|
| Poly(ADP-ribose) Polymerase Inhibitors | 1 | 2014 | 512 | 0.080 |
Why?
|
| Chromatography, High Pressure Liquid | 1 | 2011 | 590 | 0.080 |
Why?
|
| Neoplasm Metastasis | 2 | 2020 | 5308 | 0.080 |
Why?
|
| Sulfates | 2 | 1986 | 42 | 0.080 |
Why?
|
| RNA, Messenger | 6 | 2013 | 6394 | 0.080 |
Why?
|
| Acid Anhydride Hydrolases | 2 | 1999 | 84 | 0.080 |
Why?
|
| Plasmids | 3 | 2001 | 936 | 0.080 |
Why?
|
| Haplotypes | 1 | 1992 | 910 | 0.080 |
Why?
|
| Antineoplastic Agents, Immunological | 1 | 2018 | 1336 | 0.080 |
Why?
|
| Caspase 3 | 4 | 2004 | 474 | 0.080 |
Why?
|
| Neoplasm Proteins | 4 | 2004 | 3343 | 0.080 |
Why?
|
| Prostatic Neoplasms | 4 | 2010 | 5857 | 0.080 |
Why?
|
| Carcinoma | 2 | 2010 | 2607 | 0.080 |
Why?
|
| A549 Cells | 2 | 2021 | 128 | 0.080 |
Why?
|
| Carcinoma, Renal Cell | 2 | 2020 | 2388 | 0.080 |
Why?
|
| Mass Spectrometry | 1 | 2011 | 721 | 0.080 |
Why?
|
| Magnetic Resonance Spectroscopy | 1 | 2011 | 607 | 0.080 |
Why?
|
| Eukaryotic Initiation Factors | 1 | 2008 | 67 | 0.080 |
Why?
|
| Hematopoiesis | 1 | 2011 | 604 | 0.080 |
Why?
|
| Luciferases | 3 | 2013 | 460 | 0.080 |
Why?
|
| RNA, Double-Stranded | 1 | 2008 | 106 | 0.080 |
Why?
|
| Polymorphism, Genetic | 2 | 1996 | 1557 | 0.070 |
Why?
|
| Immunoenzyme Techniques | 3 | 2015 | 1185 | 0.070 |
Why?
|
| Bone Marrow Cells | 1 | 2011 | 969 | 0.070 |
Why?
|
| Lac Operon | 1 | 2007 | 133 | 0.070 |
Why?
|
| HSP70 Heat-Shock Proteins | 1 | 2008 | 163 | 0.070 |
Why?
|
| T-Lymphocytes | 4 | 2019 | 3939 | 0.070 |
Why?
|
| Organoplatinum Compounds | 1 | 2010 | 704 | 0.070 |
Why?
|
| Eye | 1 | 2009 | 283 | 0.070 |
Why?
|
| Antigens, Neoplasm | 2 | 2019 | 1580 | 0.070 |
Why?
|
| Mycobacterium bovis | 1 | 2007 | 68 | 0.070 |
Why?
|
| Interleukin-17 | 1 | 2009 | 256 | 0.070 |
Why?
|
| Fibrosarcoma | 1 | 2007 | 142 | 0.070 |
Why?
|
| Neoplasm Invasiveness | 3 | 2010 | 4044 | 0.070 |
Why?
|
| beta Catenin | 1 | 2010 | 688 | 0.070 |
Why?
|
| Fibroblasts | 4 | 2004 | 1656 | 0.070 |
Why?
|
| Sarcoma, Experimental | 2 | 2007 | 68 | 0.070 |
Why?
|
| DNA Fragmentation | 3 | 2001 | 206 | 0.070 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 1 | 2017 | 1736 | 0.070 |
Why?
|
| Exons | 3 | 2021 | 1382 | 0.070 |
Why?
|
| Sensitivity and Specificity | 2 | 2013 | 5159 | 0.070 |
Why?
|
| Mesothelioma | 2 | 2001 | 558 | 0.060 |
Why?
|
| HT29 Cells | 1 | 2006 | 157 | 0.060 |
Why?
|
| Viral Vaccines | 1 | 2009 | 358 | 0.060 |
Why?
|
| Stress, Physiological | 2 | 2020 | 493 | 0.060 |
Why?
|
| Vinblastine | 1 | 2006 | 462 | 0.060 |
Why?
|
| Esophageal Neoplasms | 2 | 2017 | 3234 | 0.060 |
Why?
|
| Antigens, CD | 1 | 2010 | 1418 | 0.060 |
Why?
|
| Survival Analysis | 3 | 2020 | 9292 | 0.060 |
Why?
|
| Immunization | 1 | 2007 | 400 | 0.060 |
Why?
|
| Metabolomics | 2 | 2021 | 505 | 0.060 |
Why?
|
| Pedigree | 4 | 1995 | 2044 | 0.060 |
Why?
|
| Melanoma, Experimental | 1 | 2008 | 382 | 0.060 |
Why?
|
| Dogs | 3 | 1996 | 1156 | 0.060 |
Why?
|
| Fatty Acid Desaturases | 1 | 2005 | 15 | 0.060 |
Why?
|
| Spindle Apparatus | 1 | 2005 | 111 | 0.060 |
Why?
|
| Dry Eye Syndromes | 1 | 2009 | 261 | 0.060 |
Why?
|
| Genes, Regulator | 2 | 2004 | 81 | 0.060 |
Why?
|
| CASP8 and FADD-Like Apoptosis Regulating Protein | 1 | 2005 | 35 | 0.060 |
Why?
|
| Recombinant Proteins | 4 | 2004 | 3027 | 0.060 |
Why?
|
| Receptors, TNF-Related Apoptosis-Inducing Ligand | 1 | 2005 | 63 | 0.060 |
Why?
|
| Survival Rate | 4 | 2019 | 12513 | 0.060 |
Why?
|
| Injections, Intralesional | 2 | 2002 | 166 | 0.060 |
Why?
|
| Genes, Retinoblastoma | 2 | 1995 | 92 | 0.060 |
Why?
|
| Inhibitor of Apoptosis Proteins | 1 | 2005 | 202 | 0.060 |
Why?
|
| Microtubules | 1 | 2005 | 330 | 0.060 |
Why?
|
| Immune System | 1 | 2005 | 275 | 0.060 |
Why?
|
| Case-Control Studies | 1 | 2013 | 6201 | 0.060 |
Why?
|
| Antineoplastic Agents, Phytogenic | 3 | 2013 | 894 | 0.060 |
Why?
|
| Interferon-gamma | 1 | 2008 | 1182 | 0.060 |
Why?
|
| Cell Line, Transformed | 1 | 2004 | 426 | 0.060 |
Why?
|
| Phosphatidylinositols | 1 | 2023 | 69 | 0.050 |
Why?
|
| Aged | 6 | 2018 | 73152 | 0.050 |
Why?
|
| Myoblasts | 1 | 2013 | 63 | 0.050 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p21 | 1 | 2004 | 537 | 0.050 |
Why?
|
| Cisplatin | 2 | 2008 | 2497 | 0.050 |
Why?
|
| Mitochondrial Proteins | 2 | 2004 | 378 | 0.050 |
Why?
|
| Antisense Elements (Genetics) | 1 | 2001 | 21 | 0.050 |
Why?
|
| Adult | 6 | 2018 | 81727 | 0.050 |
Why?
|
| Ataxia Telangiectasia Mutated Proteins | 1 | 2004 | 437 | 0.050 |
Why?
|
| Iron-Sulfur Proteins | 1 | 2001 | 22 | 0.050 |
Why?
|
| Middle Aged | 7 | 2018 | 90068 | 0.050 |
Why?
|
| Adaptor Proteins, Vesicular Transport | 1 | 2002 | 97 | 0.050 |
Why?
|
| Androgen-Binding Protein | 1 | 2001 | 34 | 0.050 |
Why?
|
| Aspartate Aminotransferases | 1 | 2002 | 146 | 0.050 |
Why?
|
| Lamins | 1 | 2001 | 9 | 0.050 |
Why?
|
| Lamin Type B | 1 | 2001 | 9 | 0.050 |
Why?
|
| Caspase 6 | 1 | 2001 | 15 | 0.050 |
Why?
|
| Energy Metabolism | 2 | 2018 | 997 | 0.050 |
Why?
|
| MCF-7 Cells | 1 | 2013 | 547 | 0.050 |
Why?
|
| Herpes Simplex Virus Protein Vmw65 | 1 | 2001 | 22 | 0.050 |
Why?
|
| Butyrates | 1 | 2001 | 57 | 0.050 |
Why?
|
| HCT116 Cells | 1 | 2022 | 354 | 0.050 |
Why?
|
| Radiation Tolerance | 2 | 2016 | 637 | 0.050 |
Why?
|
| Alanine Transaminase | 1 | 2002 | 239 | 0.050 |
Why?
|
| Gene Knockdown Techniques | 2 | 2016 | 1077 | 0.050 |
Why?
|
| Molecular Docking Simulation | 1 | 2021 | 163 | 0.050 |
Why?
|
| NIH 3T3 Cells | 1 | 2021 | 255 | 0.050 |
Why?
|
| Aged, 80 and over | 3 | 2018 | 30934 | 0.050 |
Why?
|
| Gene Silencing | 1 | 2003 | 827 | 0.040 |
Why?
|
| Glucose Transporter Type 3 | 1 | 2020 | 10 | 0.040 |
Why?
|
| Lipid Peroxidation | 1 | 2021 | 162 | 0.040 |
Why?
|
| Sulfasalazine | 1 | 2020 | 12 | 0.040 |
Why?
|
| Phosphogluconate Dehydrogenase | 1 | 2020 | 9 | 0.040 |
Why?
|
| Epithelial-Mesenchymal Transition | 2 | 2019 | 1002 | 0.040 |
Why?
|
| Glucosephosphate Dehydrogenase | 1 | 2020 | 25 | 0.040 |
Why?
|
| Aldehyde Dehydrogenase | 2 | 1992 | 104 | 0.040 |
Why?
|
| Serine Endopeptidases | 1 | 2001 | 275 | 0.040 |
Why?
|
| Acrylamides | 1 | 2020 | 68 | 0.040 |
Why?
|
| Transcriptional Activation | 2 | 2021 | 1110 | 0.040 |
Why?
|
| Transcriptome | 2 | 2021 | 1954 | 0.040 |
Why?
|
| Glucose Transporter Type 1 | 1 | 2020 | 57 | 0.040 |
Why?
|
| Gene Knockout Techniques | 1 | 2021 | 270 | 0.040 |
Why?
|
| Biphenyl Compounds | 1 | 2021 | 188 | 0.040 |
Why?
|
| Disulfides | 1 | 2020 | 111 | 0.040 |
Why?
|
| Alternative Splicing | 1 | 2003 | 612 | 0.040 |
Why?
|
| DNA, Antisense | 1 | 1999 | 44 | 0.040 |
Why?
|
| Chromatography, Thin Layer | 1 | 1999 | 69 | 0.040 |
Why?
|
| Etoposide | 2 | 2001 | 905 | 0.040 |
Why?
|
| Cell Adhesion | 2 | 2013 | 1027 | 0.040 |
Why?
|
| Proteomics | 2 | 2017 | 1425 | 0.040 |
Why?
|
| DNA Replication | 1 | 2003 | 771 | 0.040 |
Why?
|
| Adenovirus E3 Proteins | 1 | 1999 | 4 | 0.040 |
Why?
|
| Epigenesis, Genetic | 2 | 2017 | 1442 | 0.040 |
Why?
|
| Aneuploidy | 1 | 2020 | 377 | 0.040 |
Why?
|
| Enterovirus | 1 | 1999 | 56 | 0.040 |
Why?
|
| Minor Histocompatibility Antigens | 1 | 2019 | 116 | 0.040 |
Why?
|
| Receptors, Virus | 1 | 1999 | 153 | 0.040 |
Why?
|
| Gastrointestinal Agents | 1 | 2020 | 118 | 0.040 |
Why?
|
| Adenovirus E4 Proteins | 1 | 1999 | 17 | 0.040 |
Why?
|
| Pteridines | 1 | 2019 | 35 | 0.040 |
Why?
|
| Respiratory Mucosa | 1 | 2000 | 211 | 0.040 |
Why?
|
| Models, Animal | 1 | 2002 | 656 | 0.040 |
Why?
|
| Bronchi | 1 | 2000 | 324 | 0.040 |
Why?
|
| Biological Transport | 1 | 2020 | 632 | 0.040 |
Why?
|
| G2 Phase | 1 | 1999 | 218 | 0.040 |
Why?
|
| Bone Diseases, Developmental | 1 | 1989 | 70 | 0.040 |
Why?
|
| Hypoxia-Inducible Factor 1, alpha Subunit | 1 | 2020 | 395 | 0.040 |
Why?
|
| Chromosomes, Human, Pair 18 | 1 | 1999 | 189 | 0.040 |
Why?
|
| Integrin beta1 | 1 | 2019 | 128 | 0.040 |
Why?
|
| Cell Respiration | 1 | 2018 | 53 | 0.040 |
Why?
|
| Protein Folding | 1 | 2019 | 297 | 0.040 |
Why?
|
| Biosynthetic Pathways | 1 | 2018 | 48 | 0.040 |
Why?
|
| Cells, Cultured | 4 | 2011 | 5690 | 0.040 |
Why?
|
| Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alpha | 1 | 2018 | 62 | 0.040 |
Why?
|
| Minisatellite Repeats | 2 | 1995 | 66 | 0.040 |
Why?
|
| Integrins | 1 | 1999 | 275 | 0.040 |
Why?
|
| Antibodies, Viral | 2 | 1995 | 1296 | 0.040 |
Why?
|
| Myelodysplastic Syndromes | 1 | 2011 | 3148 | 0.040 |
Why?
|
| Replication Origin | 1 | 1997 | 21 | 0.040 |
Why?
|
| Immunity, Innate | 1 | 2002 | 699 | 0.040 |
Why?
|
| NF-kappa B | 1 | 2005 | 1561 | 0.040 |
Why?
|
| Intelligence | 1 | 1998 | 134 | 0.040 |
Why?
|
| DNA, Viral | 2 | 1997 | 754 | 0.040 |
Why?
|
| Tretinoin | 1 | 2000 | 618 | 0.040 |
Why?
|
| MicroRNAs | 1 | 2011 | 2889 | 0.040 |
Why?
|
| Metabolism, Inborn Errors | 1 | 1989 | 108 | 0.040 |
Why?
|
| Aspirin | 1 | 2020 | 374 | 0.040 |
Why?
|
| Endothelial Growth Factors | 1 | 1998 | 231 | 0.040 |
Why?
|
| Cell Death | 1 | 2020 | 685 | 0.040 |
Why?
|
| Metabolic Flux Analysis | 1 | 2017 | 26 | 0.040 |
Why?
|
| Analysis of Variance | 1 | 2002 | 2321 | 0.040 |
Why?
|
| Lymphokines | 1 | 1998 | 313 | 0.040 |
Why?
|
| Treatment Outcome | 1 | 2018 | 33701 | 0.040 |
Why?
|
| AMP Deaminase | 1 | 2016 | 5 | 0.040 |
Why?
|
| Peritoneal Neoplasms | 1 | 2004 | 855 | 0.040 |
Why?
|
| Vascular Endothelial Growth Factor A | 2 | 2020 | 1578 | 0.040 |
Why?
|
| Glucose Clamp Technique | 1 | 2016 | 91 | 0.040 |
Why?
|
| T-Lymphocytes, Cytotoxic | 2 | 1999 | 1016 | 0.030 |
Why?
|
| HEK293 Cells | 1 | 2021 | 1462 | 0.030 |
Why?
|
| Exosomes | 1 | 2019 | 255 | 0.030 |
Why?
|
| Antibodies | 1 | 1999 | 808 | 0.030 |
Why?
|
| Mucopolysaccharidosis IV | 2 | 1986 | 4 | 0.030 |
Why?
|
| Microscopy, Confocal | 1 | 2018 | 659 | 0.030 |
Why?
|
| Amino Acids, Branched-Chain | 1 | 2016 | 103 | 0.030 |
Why?
|
| Genetic Counseling | 1 | 1989 | 417 | 0.030 |
Why?
|
| Pleural Neoplasms | 1 | 2001 | 485 | 0.030 |
Why?
|
| Histone Code | 1 | 2016 | 86 | 0.030 |
Why?
|
| HLA Antigens | 1 | 2019 | 594 | 0.030 |
Why?
|
| Databases, Genetic | 1 | 2019 | 757 | 0.030 |
Why?
|
| Receptors, Androgen | 1 | 2001 | 855 | 0.030 |
Why?
|
| RNA-Binding Proteins | 1 | 2001 | 1017 | 0.030 |
Why?
|
| alpha 1-Antitrypsin | 1 | 1996 | 112 | 0.030 |
Why?
|
| Leukemia | 1 | 2004 | 1720 | 0.030 |
Why?
|
| Receptors, Vascular Endothelial Growth Factor | 1 | 2017 | 361 | 0.030 |
Why?
|
| Dendritic Cells | 1 | 2002 | 1109 | 0.030 |
Why?
|
| Receptors, Cell Surface | 1 | 1999 | 905 | 0.030 |
Why?
|
| DNA Probes | 2 | 1992 | 246 | 0.030 |
Why?
|
| Lactates | 1 | 2015 | 122 | 0.030 |
Why?
|
| Antibodies, Monoclonal | 1 | 2008 | 4476 | 0.030 |
Why?
|
| Adenosine Monophosphate | 1 | 2015 | 77 | 0.030 |
Why?
|
| Neutralization Tests | 1 | 1995 | 281 | 0.030 |
Why?
|
| Circadian Rhythm | 1 | 2016 | 332 | 0.030 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 2 | 2022 | 16645 | 0.030 |
Why?
|
| Receptors, LDL | 1 | 1995 | 111 | 0.030 |
Why?
|
| DNA, Recombinant | 1 | 1994 | 161 | 0.030 |
Why?
|
| Blood Coagulation | 1 | 1995 | 168 | 0.030 |
Why?
|
| Cyclosporine | 1 | 1995 | 292 | 0.030 |
Why?
|
| Burkitt Lymphoma | 1 | 2017 | 350 | 0.030 |
Why?
|
| Bone Neoplasms | 1 | 2007 | 2664 | 0.030 |
Why?
|
| Retinoblastoma | 1 | 1995 | 189 | 0.030 |
Why?
|
| Kinetics | 1 | 2017 | 2220 | 0.030 |
Why?
|
| Lymphoma, B-Cell, Marginal Zone | 1 | 2017 | 320 | 0.030 |
Why?
|
| Breast Neoplasms | 2 | 2013 | 16184 | 0.030 |
Why?
|
| Transforming Growth Factor beta | 1 | 2019 | 1109 | 0.030 |
Why?
|
| Tumor Stem Cell Assay | 1 | 2013 | 231 | 0.030 |
Why?
|
| Body Composition | 1 | 2016 | 605 | 0.030 |
Why?
|
| Recombination, Genetic | 1 | 1996 | 665 | 0.030 |
Why?
|
| Cholesterol, HDL | 1 | 1995 | 362 | 0.030 |
Why?
|
| Pancreatic Elastase | 1 | 2013 | 35 | 0.030 |
Why?
|
| Genes, Lethal | 1 | 2013 | 131 | 0.030 |
Why?
|
| Hyperlipidemias | 1 | 1995 | 223 | 0.030 |
Why?
|
| Adenosine Triphosphate | 1 | 2015 | 586 | 0.030 |
Why?
|
| Eye Neoplasms | 1 | 1995 | 257 | 0.030 |
Why?
|
| Kelch-Like ECH-Associated Protein 1 | 1 | 2013 | 118 | 0.030 |
Why?
|
| bcl-X Protein | 2 | 2004 | 198 | 0.030 |
Why?
|
| Hematopoietic Stem Cells | 1 | 2019 | 1371 | 0.030 |
Why?
|
| Transcription, Genetic | 1 | 2000 | 3341 | 0.030 |
Why?
|
| Isoenzymes | 2 | 1992 | 650 | 0.030 |
Why?
|
| Alcohol Dehydrogenase | 1 | 1992 | 34 | 0.030 |
Why?
|
| Oligonucleotide Probes | 1 | 1992 | 154 | 0.020 |
Why?
|
| Lymphocyte Activation | 2 | 2011 | 1718 | 0.020 |
Why?
|
| BH3 Interacting Domain Death Agonist Protein | 2 | 2001 | 37 | 0.020 |
Why?
|
| Stomach Neoplasms | 1 | 2004 | 2258 | 0.020 |
Why?
|
| Lymphoma, Follicular | 1 | 2017 | 636 | 0.020 |
Why?
|
| Chromosome Aberrations | 1 | 1989 | 2031 | 0.020 |
Why?
|
| Cholesterol, LDL | 1 | 1995 | 575 | 0.020 |
Why?
|
| Karyotype | 1 | 2011 | 237 | 0.020 |
Why?
|
| Tetraspanin 24 | 1 | 2010 | 4 | 0.020 |
Why?
|
| Cytokines | 2 | 2011 | 2822 | 0.020 |
Why?
|
| Microscopy, Electron, Transmission | 1 | 2011 | 240 | 0.020 |
Why?
|
| Neovascularization, Pathologic | 1 | 1998 | 1585 | 0.020 |
Why?
|
| Lymphoma, Mantle-Cell | 1 | 2017 | 749 | 0.020 |
Why?
|
| NF-E2-Related Factor 2 | 1 | 2013 | 256 | 0.020 |
Why?
|
| Tissue Array Analysis | 1 | 2013 | 757 | 0.020 |
Why?
|
| Jurkat Cells | 2 | 2001 | 320 | 0.020 |
Why?
|
| Fluorescent Antibody Technique | 1 | 2013 | 1121 | 0.020 |
Why?
|
| Genetics, Population | 1 | 1992 | 259 | 0.020 |
Why?
|
| Poxviridae | 1 | 2010 | 9 | 0.020 |
Why?
|
| Genotype | 3 | 1998 | 4251 | 0.020 |
Why?
|
| Subcellular Fractions | 1 | 2010 | 210 | 0.020 |
Why?
|
| Rats | 3 | 2007 | 6522 | 0.020 |
Why?
|
| Cell Count | 1 | 2010 | 509 | 0.020 |
Why?
|
| In Situ Nick-End Labeling | 2 | 2001 | 438 | 0.020 |
Why?
|
| Matrix Metalloproteinase 3 | 1 | 2009 | 25 | 0.020 |
Why?
|
| Carrier Proteins | 3 | 2002 | 2100 | 0.020 |
Why?
|
| Immunosuppressive Agents | 1 | 1995 | 1430 | 0.020 |
Why?
|
| Genes, Dominant | 1 | 1989 | 356 | 0.020 |
Why?
|
| Glioblastoma | 1 | 1999 | 1773 | 0.020 |
Why?
|
| Annexin A5 | 1 | 2008 | 74 | 0.020 |
Why?
|
| T-Lymphocytes, Helper-Inducer | 1 | 2009 | 219 | 0.020 |
Why?
|
| Tumor Microenvironment | 1 | 2019 | 3031 | 0.020 |
Why?
|
| DNA | 2 | 1995 | 3048 | 0.020 |
Why?
|
| Matrix Metalloproteinase 9 | 1 | 2009 | 350 | 0.020 |
Why?
|
| Rats, Mutant Strains | 1 | 2007 | 23 | 0.020 |
Why?
|
| Caspase 9 | 1 | 2008 | 187 | 0.020 |
Why?
|
| Epithelium, Corneal | 1 | 2009 | 176 | 0.020 |
Why?
|
| Conjunctiva | 1 | 2009 | 225 | 0.020 |
Why?
|
| Immunophenotyping | 1 | 2011 | 1726 | 0.020 |
Why?
|
| Child | 5 | 1998 | 30482 | 0.020 |
Why?
|
| beta-Galactosidase | 1 | 2007 | 273 | 0.020 |
Why?
|
| Glycosaminoglycans | 1 | 1986 | 71 | 0.020 |
Why?
|
| Protein Biosynthesis | 2 | 2001 | 1029 | 0.020 |
Why?
|
| Cetuximab | 1 | 2008 | 474 | 0.020 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2016 | 1415 | 0.020 |
Why?
|
| Glycogen Storage Disease | 1 | 1985 | 12 | 0.020 |
Why?
|
| Glycogen Storage Disease Type II | 1 | 1985 | 15 | 0.020 |
Why?
|
| Gaucher Disease | 1 | 1985 | 17 | 0.020 |
Why?
|
| Perfusion | 1 | 2007 | 285 | 0.020 |
Why?
|
| Time Factors | 3 | 2010 | 12989 | 0.020 |
Why?
|
| Extremities | 1 | 2007 | 309 | 0.020 |
Why?
|
| Pregnancy | 3 | 1995 | 8098 | 0.020 |
Why?
|
| Radionuclide Imaging | 1 | 1986 | 656 | 0.010 |
Why?
|
| Buthionine Sulfoximine | 1 | 2004 | 42 | 0.010 |
Why?
|
| Deoxyribonucleases | 1 | 2004 | 55 | 0.010 |
Why?
|
| Cytochromes c | 1 | 2004 | 117 | 0.010 |
Why?
|
| Actins | 1 | 2007 | 601 | 0.010 |
Why?
|
| Poly-ADP-Ribose Binding Proteins | 1 | 2004 | 117 | 0.010 |
Why?
|
| Head and Neck Neoplasms | 1 | 1999 | 4140 | 0.010 |
Why?
|
| Cornea | 1 | 2009 | 681 | 0.010 |
Why?
|
| Genes, bcl-2 | 1 | 2004 | 172 | 0.010 |
Why?
|
| Child, Preschool | 3 | 1989 | 16997 | 0.010 |
Why?
|
| Biological Assay | 1 | 2004 | 178 | 0.010 |
Why?
|
| Retroviridae | 1 | 2003 | 373 | 0.010 |
Why?
|
| Iron-Regulatory Proteins | 1 | 2001 | 11 | 0.010 |
Why?
|
| Cytotoxicity Tests, Immunologic | 1 | 2002 | 85 | 0.010 |
Why?
|
| Brain Neoplasms | 1 | 1999 | 4955 | 0.010 |
Why?
|
| Frameshift Mutation | 1 | 2003 | 235 | 0.010 |
Why?
|
| Consensus Sequence | 1 | 2001 | 116 | 0.010 |
Why?
|
| fas Receptor | 1 | 2003 | 197 | 0.010 |
Why?
|
| Formazans | 1 | 2001 | 5 | 0.010 |
Why?
|
| Bisbenzimidazole | 1 | 2001 | 8 | 0.010 |
Why?
|
| Flutamide | 1 | 2001 | 44 | 0.010 |
Why?
|
| Nucleic Acid Synthesis Inhibitors | 1 | 2001 | 47 | 0.010 |
Why?
|
| Granzymes | 1 | 2001 | 94 | 0.010 |
Why?
|
| Young Adult | 2 | 2011 | 22138 | 0.010 |
Why?
|
| Caspase 7 | 1 | 2001 | 30 | 0.010 |
Why?
|
| Staurosporine | 1 | 2001 | 147 | 0.010 |
Why?
|
| Enzyme Precursors | 1 | 2001 | 71 | 0.010 |
Why?
|
| Pancreas | 1 | 2004 | 744 | 0.010 |
Why?
|
| Biomarkers | 1 | 2012 | 5048 | 0.010 |
Why?
|
| Colon | 1 | 2004 | 680 | 0.010 |
Why?
|
| Carcinogenicity Tests | 1 | 2000 | 69 | 0.010 |
Why?
|
| Cytoplasm | 1 | 2003 | 704 | 0.010 |
Why?
|
| Indicators and Reagents | 1 | 2000 | 137 | 0.010 |
Why?
|
| Ligands | 1 | 2003 | 1016 | 0.010 |
Why?
|
| Bleomycin | 1 | 2001 | 482 | 0.010 |
Why?
|
| Blotting, Northern | 1 | 2000 | 726 | 0.010 |
Why?
|
| Glioma | 1 | 2010 | 1977 | 0.010 |
Why?
|
| Receptors, Urokinase Plasminogen Activator | 1 | 1999 | 109 | 0.010 |
Why?
|
| Radiation-Sensitizing Agents | 1 | 2001 | 366 | 0.010 |
Why?
|
| Ultraviolet Rays | 1 | 2001 | 585 | 0.010 |
Why?
|
| In Vitro Techniques | 1 | 2001 | 1716 | 0.010 |
Why?
|
| Antibody Formation | 1 | 2000 | 385 | 0.010 |
Why?
|
| Gene Expression Profiling | 1 | 2011 | 5140 | 0.010 |
Why?
|
| Spinal Muscular Atrophies of Childhood | 1 | 1989 | 23 | 0.010 |
Why?
|
| Spectrometry, Fluorescence | 1 | 1999 | 206 | 0.010 |
Why?
|
| Muscular Dystrophies | 1 | 1989 | 62 | 0.010 |
Why?
|
| Androgen Antagonists | 1 | 2001 | 419 | 0.010 |
Why?
|
| Iron | 1 | 2001 | 380 | 0.010 |
Why?
|
| Salvage Therapy | 1 | 2007 | 2123 | 0.010 |
Why?
|
| Immunity, Cellular | 1 | 2000 | 438 | 0.010 |
Why?
|
| Protein Structure, Tertiary | 1 | 2001 | 1472 | 0.010 |
Why?
|
| Vascular Endothelial Growth Factors | 1 | 1998 | 246 | 0.010 |
Why?
|
| Cytotoxicity, Immunologic | 1 | 2000 | 683 | 0.010 |
Why?
|
| Follow-Up Studies | 1 | 2013 | 15191 | 0.010 |
Why?
|
| Retrospective Studies | 1 | 2020 | 39744 | 0.010 |
Why?
|
| Loss of Heterozygosity | 1 | 1999 | 623 | 0.010 |
Why?
|
| Immunoblotting | 1 | 1998 | 893 | 0.010 |
Why?
|
| Fluorescent Dyes | 1 | 1999 | 469 | 0.010 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2008 | 3397 | 0.010 |
Why?
|
| Organoids | 1 | 1999 | 332 | 0.010 |
Why?
|
| Polymorphism, Single-Stranded Conformational | 1 | 1996 | 192 | 0.010 |
Why?
|
| Immunohistochemistry | 1 | 2007 | 7646 | 0.010 |
Why?
|
| Genetic Carrier Screening | 1 | 1995 | 101 | 0.010 |
Why?
|
| Up-Regulation | 1 | 2001 | 2421 | 0.010 |
Why?
|
| Apolipoprotein A-I | 1 | 1995 | 95 | 0.010 |
Why?
|
| Antimetabolites, Antineoplastic | 1 | 2001 | 1348 | 0.010 |
Why?
|
| Repetitive Sequences, Nucleic Acid | 1 | 1996 | 470 | 0.010 |
Why?
|
| Peptide Fragments | 1 | 2000 | 1309 | 0.010 |
Why?
|
| Rabbits | 1 | 1995 | 1047 | 0.010 |
Why?
|
| X Chromosome | 1 | 1994 | 402 | 0.010 |
Why?
|
| Drug Administration Schedule | 1 | 1998 | 3525 | 0.010 |
Why?
|
| Cloning, Molecular | 1 | 1994 | 1431 | 0.010 |
Why?
|
| Nucleic Acid Hybridization | 1 | 1992 | 631 | 0.010 |
Why?
|
| Cyclophosphamide | 1 | 1998 | 3242 | 0.010 |
Why?
|
| Korea | 1 | 1989 | 63 | 0.010 |
Why?
|
| Japan | 1 | 1989 | 235 | 0.010 |
Why?
|
| Disease Progression | 1 | 1999 | 6828 | 0.000 |
Why?
|
| China | 1 | 1989 | 638 | 0.000 |
Why?
|
| Hepatectomy | 1 | 1994 | 1012 | 0.000 |
Why?
|
| Fucosidosis | 1 | 1985 | 1 | 0.000 |
Why?
|
| alpha-L-Fucosidase | 1 | 1985 | 2 | 0.000 |
Why?
|
| alpha-Mannosidase | 1 | 1985 | 4 | 0.000 |
Why?
|
| beta-Glucosidase | 1 | 1985 | 5 | 0.000 |
Why?
|
| Clinical Enzyme Tests | 1 | 1985 | 24 | 0.000 |
Why?
|
| alpha-Glucosidases | 1 | 1985 | 31 | 0.000 |
Why?
|
| Mannosidases | 1 | 1985 | 22 | 0.000 |
Why?
|
| Infant, Newborn | 1 | 1989 | 8624 | 0.000 |
Why?
|
| Infant | 1 | 1989 | 13936 | 0.000 |
Why?
|
| Adolescent | 1 | 1989 | 32661 | 0.000 |
Why?
|